Brief: Mineralys Therapeutics Says Target-HTN Successfully Met Its Primary Endpoint
10/09/2023 12:48
Sept 10 (Reuters) - Mineralys Therapeutics Inc MLYS.O :
* MINERALYS THERAPEUTICS PRESENTS TARGET-HTN PHASE 2 TRIAL
RESULTS
IN LATE-BREAKING SCIENCE SESSION AT 2023 AHA HYPERTENSION
SCIENTIFIC SESSIONS
* TARGET-HTN SUCCESSFULLY MET ITS PRIMARY ENDPOINT
* KEY SECONDARY ENDPOINT RESULTS DEMONSTRATED A CHANGE IN
DIASTOLIC AOBP OF -7.1 MMHG WITH 50MG
* OTHER SECONDARY ENDPOINTS, INCLUDING ASSESSMENT OF 24-HOUR
AVERAGE BP, SUPPORTED EFFICACY OF QD DOSING REGIMEN.
Source text for Eikon: ID:nGNX9DYjB7
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway